Literature DB >> 24508837

Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population.

Kristi Huik1, Radko Avi, Helen Uibopuu, Merit Pauskar, Tõnu Margus, Tõnis Karki, Tõnu Krispin, Piret Kool, Kristi Rüütel, Ave Talu, Katri Abel-Ollo, Anneli Uusküla, Andrew Carrillo, Weijing He, Sunil K Ahuja, Irja Lutsar.   

Abstract

BACKGROUND: The influence of the diversity of CCR5 on HIV susceptibility and disease progression has been clearly demonstrated but how the variability of this gene influences the HIV tropism is poorly understood. We investigated whether CCR5 haplotypes are associated with HIV tropism in a Caucasian population.
METHODS: We evaluated 161 HIV-positive subjects in a cross-sectional study. CCR5 haplotypes were derived after genotyping 9 CCR2-CCR5 polymorphisms. The HIV subtype was determined by phylogenetic analysis using the maximum likelihood method and viral tropism by the genotypic tropism assay (geno2pheno). Associations between CCR5 haplotypes and viral tropism were determined using logistic regression analyses. Samples from 500 blood donors were used to evaluate the representativeness of HIV-positives in terms of CCR5 haplotype distribution.
RESULTS: The distribution of CCR5 haplotypes was similar in HIV-positive subjects and blood donors. The majority of viruses (93.8%) belonged to HIV-1 CRF06_cpx; 7.5% were X4, and the remaining were R5 tropic. X4 tropic viruses were over represented among people with CCR5 human haplotype E (HHE) compared with those without this haplotype (13.0% vs 1.4%; P = 0.006). People possessing CCR5 HHE had 11 times increased odds (odds ratio = 11.00; 95% confidence interval: 1.38 to 87.38) of having X4 tropic viruses than those with non-HHE. After adjusting for antiretroviral (ARV) therapy, neither the presence of HHE nor the use of ARV was associated with X4 tropic viruses.
CONCLUSIONS: Our results suggest that CCR5 HHE and ARV treatment might be associated with the presence of HIV-1 X4 tropic viruses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24508837      PMCID: PMC4146654          DOI: 10.1097/QAI.0000000000000127

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

1.  Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4.

Authors:  B Shieh; Y E Liau; P S Hsieh; Y P Yan; S T Wang; C Li
Journal:  Int Immunol       Date:  2000-09       Impact factor: 4.823

2.  CCR5 delta32 heterozygosity is associated with an increase in CXCR4 cell surface expression.

Authors:  Sharon Shalekoff; Caroline T Tiemessen
Journal:  AIDS Res Hum Retroviruses       Date:  2003-06       Impact factor: 2.205

3.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Authors:  Janelle R Salkowitz; Shannon E Bruse; Howard Meyerson; Hernan Valdez; Donald E Mosier; Clifford V Harding; Peter A Zimmerman; Michael M Lederman
Journal:  Clin Immunol       Date:  2003-09       Impact factor: 3.969

4.  Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.

Authors:  S Mummidi; M Bamshad; S S Ahuja; E Gonzalez; P M Feuillet; K Begum; M C Galvis; V Kostecki; A J Valente; K K Murthy; L Haro; M J Dolan; J S Allan; S K Ahuja
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

5.  CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression.

Authors:  J Reynes; P Portales; M Segondy; V Baillat; P André; O Avinens; M C Picot; J Clot; J F Eliaou; P Corbeau
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

6.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

7.  Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.

Authors:  A Mangano; E Gonzalez; R Dhanda; G Catano; M Bamshad; A Bock; R Duggirala; K Williams; S Mummidi; R A Clark; S S Ahuja; M J Dolan; R Bologna; L Sen; S K Ahuja
Journal:  J Infect Dis       Date:  2001-05-02       Impact factor: 5.226

8.  Response to treatment and disease progression linked to CD4+ T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection.

Authors:  Alain Gervaix; Joelle Nicolas; Pierre Portales; Klara Posfay-Barbe; Claire-Anne Wyler; Michel Segondy; Odile Avinens; Claire-Anne Siegrist; Jacques Clot; Jean-François Eliaou; Jacques Astruc; Pierre Corbeau
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

9.  Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men.

Authors:  I J Spijkerman; M Koot; M Prins; I P Keet; A J van den Hoek; F Miedema; R A Coutinho
Journal:  AIDS       Date:  1995-09       Impact factor: 4.177

10.  CCR5 promoter human haplogroups associated with HIV-1 disease progression in Thai injection drug users.

Authors:  Lily Nguyen; Ming Li; Thanyanan Chaowanachan; Dale J Hu; Suphak Vanichseni; Philip A Mock; Frits van Griensven; Michael Martin; Udomsak Sangkum; Kachit Choopanya; Jordan W Tappero; Renu B Lal; Chunfu Yang
Journal:  AIDS       Date:  2004-06-18       Impact factor: 4.177

View more
  1 in total

1.  CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea.

Authors:  Noemi B Hall; Shannon E Bruse; Bangan John; Rajeev K Mehlotra; Melinda J Blood Zikursh; Catherine M Stein; Peter M Siba; Peter A Zimmerman
Journal:  Infect Genet Evol       Date:  2015-09-28       Impact factor: 3.342

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.